[Show abstract] [Hide abstract]
ABSTRACT: Endoscopic treatment is increasingly being accepted for early Barrett's cancer (EBC), as it is associated with few complications, excellent long-term results, and almost no mortality. This study investigated current standards and treatment strategies for EBC in eight countries in Western Europe.
A standardized questionnaire with questions on the endoscopic diagnosis, staging, and treatment of EBC was developed and sent to 107 university gastroenterology departments. The data were analyzed anonymously.
The response rate was 49 % (52/107). For work-up of early Barrett's neoplasia, 67 % of hospitals use high-resolution endoscopes, with routine four-quadrant and targeted biopsies of visible lesions in 94 % of the cases. Narrow-band imaging and chromoendoscopy are used in 67 % of the cases, and other advanced imaging and staining techniques in 65 %. Before treatment, 63 % of the respondents recommended conventional endosonography, 6 % miniprobe endosonography, and 19 % both. Endoscopic resection is carried out at 98 % of the hospitals. Argon plasma coagulation is used for ablation in 52 % of the cases and radiofrequency ablation in 27 %. An 80-year-old patient with localized mucosal EBC would be treated endoscopically in all of the hospitals. Endoscopic therapy was recommended for 50-year-old patients with mucosal EBC by 87 % of the hospitals; esophageal resection was recommended for multifocal EBC by 15 % in 80-year-old patients, by 63 % in 50-year-old patients and by 44 % in patients with incipient submucosal infiltration.
About two-thirds of the university hospitals use high-resolution endoscopy and advanced imaging. Endoscopic therapy is the accepted standard for treating localized mucosal Barrett's cancer in Western Europe; esophageal resection is recommended by the majority (63 %) for a young patient with multifocal EBC.
Zeitschrift für Gastroenterologie 07/2012; 50(7):670-6. · 1.41 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Despite progress in recent years in the diagnostics, surgical treatment and intensive care therapy, severe acute pancreatitis remains a major challenge to the medical profession and a serious threat to the patients. In its most severe form, acute pancreatitis is characterised by a profound inflammatory process in the pancreas leading to partial or total necrosis of the parenchyma. Acute pancreatitis also frequently causes dysfunction of remote organs as well as local complications (pancreatic infection, haemorrhage and pseudocysts). The majority of the attacks of acute pancreatitis (85-90%) are, however, mild and can be dealt with by simple routine treatment. It is essential to identify at an early stage those patients who will develop a severe form of the disease, to allow timely vital organ system monitoring and support in an intensive care unit. Early intervention may have a significant influence on the course of the disease. As soon as the pancreatic inflammation has progressed to necrosis, anti-enzyme or anti-inflammatory therapy and/or treatment which may enhance the pancreatic microcirculation is not likely to change the course of the disease and leaves the treating physician with symptomatic measures only. On arrival to the ICU the patients are frequently hypovolaemic, have diminished blood flow to the abdominal organs, resulting not only in more severe local disease, but also frequently causing failure of remote organs such as the lungs (adult respiratory distress syndrome), kidneys, liver and the intestine (possibly encouraging translocation of enteral bacteria). The aim of therapy in severe pancreatitis is obviously to halt the progress of the local disease and to prevent remote organ failure. So far, very limited experimental and clinical research has been performed on the effects of different modes of intensive care therapy on pancreatic blood flow or on the progress of the panceatic necrosis. Based on clinical experience and available research data, the following procedures are currently recommended in the ICU management of severe pancreatitis. (l)Use invasive monitoring. (2) Optimise oxygen transport by maintaining hyperdynamic circulation (at least during the first 3 days), for example by using isovolaemic or hypervolaemic haemodilution, administration of low dose dopexamine and if necessary other cardio-inotropic drugs. (3) Indications for assisted ventilation should be liberal in order to guarantee high blood oxygen content and to decrease energy expenditure. (4) Start nutrition early to minimise negative nitrogen balance, but avoid overfeeding. (5) Use crystalloids for replacement of insensible fluid loss only and synthetic colloids such as pentastarch for plasma substitution. (6) Provide effective pain relief, for example, by continuous epidural or coeliac block. (7) In cases of extensive necrosis, prophylactic antibiotic therapy (imipenem) should be considered. (8) Follow the clinical course of the patient very closely and monitor the degree of necrosis and possible pancreas infection for timely surgical intervention when necessary.Copyright © 1994 S. Karger AG, Basel
DMW - Deutsche Medizinische Wochenschrift 06/2012; 137(22):1171-3. · 0.65 Impact Factor
Gastrointestinal Endoscopy 04/2011; 73(4). · 5.21 Impact Factor
Zeitschrift für Gastroenterologie 08/2010; 48(08). · 1.41 Impact Factor
Zeitschrift Fur Gastroenterologie - Z GASTROENTEROL. 01/2010; 48(08).